ARF like GTPase 14 effector protein likeGenealiases: []
Q-omics provides the consensus-scored ARL14EPL profile across patient tissues and cancer cell-line models. ARL14EPL expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARL14EPL is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ARL14EPL RNA expression shows 7,935 significant gene co-expression associations, with the highest sampling consensus in THCA. Together, these results highlight KIRC, and THCA as cancer lineages where ARL14EPL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL14EPL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL14EPL survival associations across molecular data types. ARL14EPL RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL14EPL RNA expression–survival associations across cancer types. High ARL14EPL expression shows unfavorable associations in KIRC, LUSC, THYM, KIRP, MESO and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARL14EPL RNA expression.
This table summarizes ARL14EPL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARL14EPL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL14EPL shows lower tumor expression in KIRC, KICH and LUSC and higher tumor expression in THCA, HNSC and UCEC. The KIRC box plot shows higher ARL14EPL RNA expression in normal versus tumor tissue (log2 FC = −0.358, t-test p < 0.001).
This table shows molecular features associated with ARL14EPL in patient tissues and cancer cell lines. In patient samples, ARL14EPL shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ARL14EPL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and PANCREAS.
